Welcome to our dedicated page for NERVGEN PHARMA news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on NERVGEN PHARMA stock.
NervGen Pharma Corp (symbol: NGENF) is a clinical-stage biotech company focused on developing cutting-edge solutions for treating nervous system damage. Their lead drug candidate, NVG-291, is currently in a Phase 1b/2a clinical trial, targeting spinal cord injury as the initial indication. The company recently reported its financial and operational results, highlighting progress in recruitment for their clinical study and receiving Fast Track designation from the FDA. With a strong focus on innovative treatments and dedicated research efforts, NervGen is committed to enabling the nervous system to repair itself in cases of injury or disease.
Rhea-AI Summary
NervGen Pharma Corp. (NGEN) reports progress in NVG-291 clinical trial for spinal cord injury, receiving Fast Track designation from FDA. John Ruffolo appointed to the Board. Financial and operational results for Q3 2023 also announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.8%
Tags
-
Rhea-AI Summary
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) announces Dr. Jerry Silver's interview with Guy Kawasaki on 'Remarkable People' podcast, discussing NVG-291, a drug candidate for spinal cord injury. Dr. Silver's groundbreaking work has led to a Phase 1b/2a clinical trial for NVG-291, with initial results expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.4%
Tags
-
Rhea-AI Summary
NervGen Pharma has received Fast Track designation from the FDA for its lead compound, NVG-291, in individuals with spinal cord injury. The designation aims to expedite the development of drugs for serious conditions and unmet medical needs. NVG-291 has the potential to be the first approved treatment for neurological/functional recovery after spinal cord injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.62%
Tags
Rhea-AI Summary
NervGen Pharma appoints John Ruffolo, Founder and Managing Partner of Maverix Private Equity, to its Board of Directors. Ruffolo brings extensive experience in private equity and venture capital, as well as personal knowledge of spinal cord injury. NervGen is currently conducting a clinical trial for its drug NVG-291 for spinal cord injury treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
-
Rhea-AI Summary
NervGen Pharma begins Phase 1b/2a trial for spinal cord injury treatment NVG-291, with results expected in mid-2024 and late 2024/early 2025 for chronic and subacute cohorts respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
-
Rhea-AI Summary
NervGen Pharma's Chief Medical Officer to present at International Spinal Research Trust Network Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
Rhea-AI Summary
NervGen Pharma to present at H.C. Wainwright conference, offering one-on-one investor meetings. Webcast available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
-
Rhea-AI Summary
NervGen Pharma to present at KOL Discussion on Spinal Cord Injury
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
-
Rhea-AI Summary
NervGen Pharma Corp. reports financial and operational results for Q2 2023. Landmark Phase 1a/2b clinical trial of NVG-291 for spinal cord injury proceeds with recruitment. Results expected in mid-2024. Mike Kelly appointed as President & CEO. Grant of up to US$3.18 million awarded from Wings for Life to support clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.8%
Tags
FAQ
What is the current stock price of NERVGEN PHARMA (NGENF)?
The current stock price of NERVGEN PHARMA (NGENF) is $1.8 as of October 15, 2024.
What is the market cap of NERVGEN PHARMA (NGENF)?
The market cap of NERVGEN PHARMA (NGENF) is approximately 138.3M.
What is NervGen Pharma Corp focused on?
NervGen Pharma Corp is dedicated to developing innovative solutions for the treatment of nervous system damage.
What is NVG-291, and what is its current status?
NVG-291 is the lead drug candidate of NervGen Pharma Corp, currently undergoing evaluation in a Phase 1b/2a clinical trial for spinal cord injury.
What recent achievements has NervGen reported?
NervGen recently received Fast Track designation from the FDA and reported positive progress in their recruitment efforts for the clinical study.
What sets NervGen apart in the biotech industry?
NervGen's focus on enabling the nervous system to repair itself post-injury or disease and their commitment to innovative treatments differentiate them in the biotech landscape.
NERVGEN PHARMA CORP